Category: Hypertension
Poster Session I
Hypertensive disorders of pregnancy (HDP) remain a leading cause of maternal morbidity worldwide and across diverse populations. Dyslipidemia has been associated with HDP; however, observational studies are susceptible to residual confounding and few randomized controlled trials have been conducted. Mendelian randomization (MR) analyses use genetic variants as instrumental variables to create a pseudo-randomized experiment. In this study, we estimate the association between genetically predicted lipid values, their pharmacological targets, and the risk of HDP.
Study Design: We extracted uncorrelated (R2 < 0.001) single-nucleotide polymorphisms (SNPs) strongly associated (p-value < 5e-8) with high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) from published genome-wide association studies of European, admixed African, Latino, and East Asian ancestry participants. Similar extraction was done for lipid-modifying drug targets among European participants. An inverse-variance weighted analysis was performed, and results were meta-analyzed across ancestry groups. Several sensitivity analyses were conducted to evaluate bias due to genetic pleiotropy.
Results: The meta-analysis across four ancestry groups included 1.5 million subjects with lipid measurements, 7,425 subjects with HDP and 239,290 without HDP. Lower genetically predicted HDL-C and higher genetically predicted TG were associated with increased risk of HDP, respectively (odds ratio [OR] 0.84; 95% CI 0.74-0.94; p=0.004, and OR 1.29; 95% CI 1.12-1.49; p< 0.001) (Figure 1). However, only the effect of HDL-C was consistent in the sensitivity analysis (data not shown). For the lipid-modifying genetic drug targets, only those targeting HDL-C were significant (Table 1).
Conclusion:
Robust MR analyses demonstrate a likely protective effect of elevated HDL-C on risk of HDP. This relationship was fairly consistent across different ancestry groups. These findings provide insight into a potentially new target for screening and intervention.
Hillary Hosier, MD
Fellow
Yale University School of Medicine
New Haven, Connecticut, United States
Heather S. Lipkind, MD, MS
Associate Professor
Yale University School of Medicine
New York, New York, United States
Andrew T. DeWan, MPH, PhD
Center for Perinatal, Pediatric and Environmental Epidemiology at Yale School of Public Health
New Haven, Connecticut, United States
Tormod Rogne, MD, PhD
Center for Perinatal, Pediatric and Environmental Epidemiology at Yale School of Public Health
New Haven, Connecticut, United States